



Ciriaco Maraschiello joins Axxam as Chief Operating Officer

July 5th, 2023 - Axxam S.p.A. (Milan/Italy), the innovative Partner Research Organization (iPRO) announced the appointment of Dr. Ciriaco Maraschiello as Chief Operating Officer (“COO”).

In his role, Ciriaco will report to Dr. Stefan Lohmer, Axxam’s Chief Executive Officer, and will join the Executive Committee of the Company. His responsibilities will be on implementing company strategies into daily operations to meet objectives, with reference to the two sites in Italy (Milan, Naples) and the one in Germany (Constance).

Ciriaco brings to Axxam more than 25 years of industry experience within the Contract Research Organization business segment. He started his career within the Pharmaceutical business in 1997 after completing a PhD in Biochemistry within the framework of a Marie Curie EU fellowship. Ciriaco has a strong background in ADME, preclinical safety assessment and formulation and obtained an executive MBA in 2017 from the Bocconi University (Milan, Italy). During his professional tenure, Ciriaco occupied several scientific and leadership/managerial positions within the pharmaceutical R&D value stream. As an executive, he held global operational roles leading large international teams across Europe and Asia in Cidasal (ES), RCC (CH), Harlan (US), Aptuit (US) and Evotec (DE). His leadership is characterized by a strong focus on people and value creation.

Ciriaco Maraschiello said: *“I am very excited to join Axxam and to have the opportunity to contribute in writing the next chapter of the Company together with its highly qualified people and teams. A future characterized by growth and impact within the pharmaceutical research from an early discovery perspective with a strong focus improving constantly the quality of life on our planet. I look forward to work with Axxam’s Executive Team to make this happen”.*

Stefan Lohmer, Chief Executive Officer of Axxam stated: *“We are thrilled to welcome Ciriaco as Chief Operating Officer. With his exceptional leadership skills, scientific expertise and extensive industrial experience, we are confident that he will play a crucial role within our Executive Team, driving the company to new heights of growth. As we embark on the next phase of our 20 years journey, our objective remains steadfast: to become the foremost, cutting-edge, biology-centric integrated research company. Our commitment spans from target assessment to lead discovery, as we strive for excellence in every step”.*

About Axxam

Axxam is an innovative Partner Research Organization (iPRO) providing integrated discovery services across the life sciences industries. Axxam is headquartered in the Milan area (Italy), with other research laboratories in Naples (Italy) as well as Constance (Germany) and business offices in Cambridge (MA, USA), Copenhagen (Denmark) and Basel (Switzerland). Within the drug discovery disciplines, Axxam supports pharma and biotech companies, start-ups, patient foundations as well as academic groups in their journey from target assessment and hit identification to lead generation, over all therapeutic areas and target classes. Axxam’s services include assay development, high-throughput screening, hit validation and hit-to-lead. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information, please visit www.axxam.com